C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter L—Regulations Under Certain Other Acts Administered By the Food and Drug AdministrationPart 1271—Human Cells, Tissues, And Cellular and Tissue-Based ProductsSubpart A—General Provisions

21 C.F.R. § 1271.10 (2026)

Are my HCT/P's regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do?

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 7 IN 5Y cited 2012–2026 10citing cases
At a glance

Courts have cited this section in 10 opinions since 2012, 7 of them in the last five years.

(a) An HCT/P is regulated solely under section 361 of the PHS Act and the regulations in this part if it meets all of the following criteria:

(1) The HCT/P is minimally manipulated;

(2) The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent;

(3) The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and

(4) Either:

(i) The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or

(ii) The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and:

(a) Is for autologous use;

(b) Is for allogeneic use in a first-degree or second-degree blood relative; or

(c) Is for reproductive use.

(b) If you are a domestic or foreign establishment that manufactures an HCT/P described in paragraph (a) of this section:

(1) You must register with FDA;

(2) You must submit to FDA a list of each HCT/P manufactured; and

(3) You must comply with the other requirements contained in this part.

[66 FR 5466, Jan. 19, 2001, as amended at 69 FR 68681, Nov. 24, 2004]
The 10 cases that cite 21 C.F.R. § 1271.10 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUnited States v. US Stem Cell Clinic, LLC, 998 F.3d 1302 (11th Cir. 2021).
cites § 1271.10 4×cited by 4 cases
Where it cites § 1271.10
“The second provision is 21 C.F.R. § 1271.10 , which subjects HCT/Ps meeting each of several criteria to a lighter regulatory burden.”
2
GREENUnited States v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014).
cites § 1271.10 2×cited by 15 cases
Where it cites § 1271.10
“” 3 See 21 C.F.R. § 1271.10 (a). “Minimal manipulation” of cells means “processing that does not alter the relevant biological characteristics.”
Later courts cite it for
“would be unnecessary if the fdca did not otherwise regulate the distribution of drugs by licensed physicians.” · 1 citing court
3
GREENUnited States v. Regenerative Sciences, LLC, 878 F. Supp. 2d 248 (D.D.C. 2012).
cites § 1271.10 3×cited by 6 cases
Where it cites § 1271.10
“Those HCT/Ps that meet the set of criteria listed in 21 C.F.R. § 1271.10 are only regulated under section 361 of the PHSA and Part 1271 of the C.”
Later courts cite it for
“to constitute final agency action, two conditions must be met: (1) 'the action must mark the consummation of the agency's decisionmaking process' and (2) it 'must be one by which rights or obligations have been determined, or from which legal consequences will flow.” · 2 citing courts
4
cites § 1271.10 2×cited by 3 cases
Where it cites § 1271.10
“21 C.F.R. §§ 1271.10 (a)(2)-(4), 1271.3(c).”
5
GREENRow 1 Inc. v. Xavier Becerra, 92 F.4th 1138 (D.C. Cir. 2024).
cites § 1271.10 1×cited by 6 cases
Where it cites § 1271.10
“See 21 C.F.R. § 1271.10 (a). Regenative believes its products are minimally manipulated and fit these criteria, and the Complaint asserts that, “[t]o date, the FDA has not .”
6
NO FLAGUnited States v. California Stem Cell Treatment Ctr., Inc., 624 F. Supp. 3d 1177 (C.D. Cal. 2022).
cites § 1271.10 1×cited by 0 casesunknown
Where it cites § 1271.10
“19 Any reference to whether the HCT/Ps are manipulated and/or altered are 20 located in a different, inapplicable, regulation 21 C.F.R. § 1271.10 (discussing 21 “minimal manipulation”).”
7
NO FLAGMoreno v. Polarityte, No. 2:18-cv-00510 (D. Utah Nov. 22, 2020).
cites § 1271.10 1×cited by 0 casesunknown
Where it cites § 1271.10
“21 C.F.R. § 1271.10 (a). Unlike HCT/Ps registered under Section 351, HCT/Ps registered “under Section 361 are not required to obtain premarket approval/clearance from the FDA and do not require the extensive registration, manufacturing, and reporting steps required [for…”
8
NO FLAGRichfield v. Polarityte, No. 2:21-cv-00561 (D. Utah Apr. 19, 2023).
cites § 1271.10 1×cited by 0 casesunknown
Where it cites § 1271.10
“FDA announced at that time that it would exercise enforcement discretion for a limited period and allow manufacturers to market an HCT/P under Section 361 even if the HCT/P did not meet all the requitements under 21 C.F.R. § 1271.10 (a), as long as the use of the HCT/P did not…”
9
NO FLAGGreiner Orthopedics, LLC v. Becerra, No. 2023-1047 (D.D.C. Jan. 8, 2026).
cites § 1271.10 1×cited by 0 cases
Where it cites § 1271.10
“21 C.F.R. § 1271.10 (a) (2004). Manufacturers of HCT/Ps meeting these criteria are required only to comply with certain registration and reporting regulations.”
10
NO FLAGMacOmb Foot v. Becerra, No. 2024-0869 (D.D.C. Mar. 31, 2026).
cites § 1271.10 1×cited by 0 cases
Where it cites § 1271.10
“The Appeals Council deemed the ALJ’s findings “conclusory” and “incomplete,” as the ALJ “did not analyze the strength of the appellant-provided medical literature” but rather “focused on appellant’s compliance with 21 C.F.R. § 1271.10 (a) and [Section 361] to find Corplex P not…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
201220192026

One bar per year. Tallest: 2 cases in 2024. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.3D.C. Cir.2D. Utah211th Cir.19th Cir.1C.D. Cal.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com